Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Operating Income (2023 - 2025)

Historic Operating Income for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to -$60.1 million.

  • Immunome's Operating Income fell 1903.33% to -$60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$234.2 million, marking a year-over-year increase of 2622.53%. This contributed to the annual value of -$305.8 million for FY2024, which is 17919.29% down from last year.
  • Immunome's Operating Income amounted to -$60.1 million in Q3 2025, which was down 1903.33% from -$46.5 million recorded in Q2 2025.
  • Over the past 5 years, Immunome's Operating Income peaked at -$4.5 million during Q1 2023, and registered a low of -$132.3 million during Q1 2024.
  • In the last 3 years, Immunome's Operating Income had a median value of -$46.5 million in 2025 and averaged -$51.5 million.
  • Its Operating Income has fluctuated over the past 5 years, first plummeted by 285904.72% in 2024, then surged by 6626.13% in 2025.
  • Over the past 3 years, Immunome's Operating Income (Quarter) stood at -$94.7 million in 2023, then increased by 12.34% to -$83.0 million in 2024, then increased by 27.52% to -$60.1 million in 2025.
  • Its Operating Income was -$60.1 million in Q3 2025, compared to -$46.5 million in Q2 2025 and -$44.6 million in Q1 2025.